{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-112973","form_type":"8-K","ticker":"DFTX","cik":"0001813814","company_name":"Definium Therapeutics, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.087973+00:00","generated_at":"2026-05-17T08:20:48.303735+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints","bullets":["MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.","Phase 2b study in 198 adults with moderate-to-severe GAD met primary and key secondary endpoints; dose-response demonstrated.","MM120 was well-tolerated; adverse events mild-to-moderate, transient, consistent with LSD effects.","FDA granted Breakthrough Therapy Designation for MM120 in GAD; Phase 3 trials (Voyage, Panorama, Emerge) enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-112973","json":"https://secwatch.observer/filing/0000950170-25-112973.json","markdown":"https://secwatch.observer/filing/0000950170-25-112973.md","text":"https://secwatch.observer/filing/0000950170-25-112973.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/0000950170-25-112973-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1813814/000095017025112973/mnmd-20250904.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:20:48.303735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}